Paul Collins is a Senior Director in Small Molecule Design and Development at Eli Lilly and Company in Indianapolis. Paul has responsibility for both drug product and API process development activities for Lilly’s small molecule portfolio. He is also responsible for continuous manufacturing development and ensuring these technologies are applied to portfolio development work. Paul started his career with Merck and Company, working in both manufacturing and R&D. Across both companies, Paul has been involved in the process development, registration, and commercialization of six marketed pharmaceuticals. Paul has been heavily involved with AIChE over the past decade, chairing the Pharmaceutical Forum for 2015 and 2016, and creating the first FDA-AIChE co-sponsored meeting on continuous manufacturing adoption. Paul received his BE in Chemical Engineering from Vanderbilt University and his PhD from Northwestern University.